Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein 3 pseudogene 3 (BNIP3P3) is annotated as a pseudogene, not a protein-coding gene or therapeutic target. Pseudogenes, by definition, are homologous genomic DNA sequences similar to a functional gene but typically do not encode functional proteins due to mutations or lack of regulatory elements for gene expression. BNIP3P3 is related in sequence to BCL2 interacting protein 3 (BNIP3), but unlike BNIP3, there is no evidence it encodes a functional protein or participates in regulatory or disease pathways. Currently, there are no reported biological functions, interacting drugs, disease associations, biomarker utility, or therapeutic relevance for BNIP3P3. If the intention was to refer to BNIP3 as a drug target, the correct canonical name would be BCL2 interacting protein 3 (BNIP3), not BNIP3P3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 3 (BNIP3P3).